Costa, Luciano J.

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.

San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M.-V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., et al. (2023) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsCAR-T cell therapy research

Cited by 827

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

Rodriguez-Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., et al. (2023) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsCAR-T cell therapy research

Cited by 781

Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma

Chari, A., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Askari, E., Mateos, M.-V., Costa, L. J., Caers, J., et al. (2022) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 744

Oral selinexor-dexamethasone for triple-class refractory multiple myeloma.

Chari, A., Vogl, D. T., Gavriatopoulou, M., Nooka, A. K., Yee, A. J., Huff, C. A., Moreau, P., Dingli, D., Cole, C., Lonial, S., et al. (2019) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 666

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.

Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., Gupta, R., Varnado, W., Fiala, M. A., Chhabra, S., et al. (2019) · Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 616

Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2019) · Journal of the National Comprehensive Cancer Network

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 570

Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study

Trudel, S., Cohen, A. D., Krishnan, A. Y., Fonseca, R., Spencer, A., Berdeja, J. G., Lesokhin, A., Forsberg, P. A., Laubach, J. P., Costa, L. J., et al. (2021) · Blood

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 165

Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).

Mailankody, S., Jakubowiak, A. J., Htut, M., Costa, L. J., Lee, K., Ganguly, S., Kaufman, J. L., Siegel, D. S. D., Bensinger, W., Cota, M., et al. (2020) · Journal of Clinical Oncology

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 126

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

Costa, L. J., Bahlis, N. J., Perrot, A., Nooka, A. K., Lu, J., Pawlyn, C., Mina, R., Caeiro, G., Kentos, A., Hungria, V., et al. (2026) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 119

Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study.

Chari, A., Touzeau, C., Schinke, C., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Morillo, D., Martinez-Chamorro, C., et al. (2025) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 116

Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses.

Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., Bahlis, N. J., et al. (2024) · Blood

Multiple Myeloma Research and TreatmentsCAR-T cell therapy research

Cited by 79

BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study

Bal, S., Htut, M., Nadeem, O., Anderson, L. D., Koçoğlu, H., Gregory, T., Rossi, A. C., Martin, T., Egan, D. N., Costa, L., et al. (2023) · Blood

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 59

Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity

Costa, L. J., Hari, P. N., & Kumar, S. K. (2016) · Leukemia & Lymphoma

Multiple Myeloma Research and TreatmentsEthics in Clinical Research

Cited by 57

Efficacy and Safety of Less Frequent/Lower Intensity Dosing of Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Phase 1/2 MonumenTAL-1 Study

Chari, A., Oriol, A., Krishnan, A., Martinez Chamorro, M. D. C., Costa, L., Mateos, M. V., Minnema, M. C., Campagna, M., Masterson, T. J., Hilder, B. W., et al. (2023) · Blood

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 51

Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study

Bal, S., Kocoglu, M. H., Nadeem, O., Htut, M., Gregory, T., Anderson, L. D., Costa, L. J., Buchholz, T. J., Ziyad, S., Li, M., et al. (2022) · Blood

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 38

Use of complementary and alternative medicine by Brazilian oncologists

SAMANO, E. S. T., RIBEIRO, L. M., CAMPOS, A. S., LEWIN, F., FILHO, E. S. V., GOLDENSTEIN, P. T., COSTA, L. J. M., & DEL GIGLIO, A. (2005) · European Journal of Cancer Care

Complementary and Alternative Medicine StudiesTraditional Chinese Medicine Clinical Research

Cited by 23

Atezolizumab in Combination with Daratumumab with or without Lenalidomide or Pomalidomide: A Phase Ib Study in Patients with Multiple Myeloma

Cho, H. J., Costa, L. J., Davies, F. E., Neparidze, N., Vij, R., Feng, Y., Teterina, A., Wassner Fritsch, E., Wenger, M., & Kaufman, J. L. (2018) · Blood

Multiple Myeloma Research and TreatmentsCancer Immunotherapy and Biomarkers

Cited by 21